Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
Data shared from phase II NEO trial highlights Guardant Reveal™ as a decision tool to support organ preservation in rectal cancer
PALO ALTO, Calif.–(BUSINESS WIRE)–
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant’s precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025.
Key focus areas in Guardant’s co-authored abstracts and collaborator presentations utilizing Guardant products include the impact of mutations on treatment response in colorectal cancer and biliary tract cancers, and additional support for the benefits of blood-based screening in colorectal, gastric and esophageal cancers. A rapid oral presentation will feature data from the phase II NEO trial highlighting Guardant Reveal as a decision tool to support organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision and observation.
“Data increasingly supports the value of precision oncology tools, and specifically liquid biopsy, in detecting GI cancers, informing treatment selection, and monitoring for recurrence and therapy response,” said Craig Eagle, MD, Guardant Health chief medical officer. “Findings presented at ASCO GI demonstrate the advancements being made by Guardant Health and our partners in these areas and show the potential for these tools to provide even more personalized cancer care, leading to better patient outcomes.”
Guardant Health ASCO GI 2025 Co-Authored Posters and Presentations
|
Time and Location |
Title |
Abstract and Presentation Type |
|
Guardant Reveal |
||
|
January 25, 2025 9:15 – 10:00 am PST Level 2, Ballroom |
Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28) |
Rapid Oral Abstract Session C Abstract #20 |
|
Guardant360® |
||
|
January 25, 2025 7:00 – 7:55 am PST Level 1, West Hall |
Retrospective study evaluating the genomic landscape of anal squamous cell carcinoma using liquid biopsy |
Poster Session C Abstract #8 |
|
Landscape of metastatic colorectal cancer (CRC) using comprehensive circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in India: Expanding beyond RAS and RAF |
Poster Session C Abstract #49 |
|
|
GuardantINFORM™ |
||
|
January 24, 2025 11:30 am – 1:00 pm PST Level 1, West Hall |
Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy |
Poster Session B Abstract #548 |
|
ShieldTM |
||
|
January 25, 2025 7:00 – 7:55 am PST Level 1, West Hall |
Cost-effectiveness of blood-based colorectal cancer screening: A simulation model incorporating real-world longitudinal adherence |
Poster Session C Abstract #93 |
|
A method for classifying colorectal cancer and gastric/esophageal cancer using blood-based testing |
Poster Session C Abstract #52 |
|
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO GI 2025 can be found on the ASCO website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123880822/en/
Investor Contact:
Zarak Khurshid
[email protected]
Media Contact:
Michael Weist
[email protected]
+1 317-371-0035
KEYWORDS: California United States North America
INDUSTRY KEYWORDS: Research Medical Devices Clinical Trials Health Technology Biotechnology Health Pharmaceutical Science Oncology
MEDIA:
| Logo |
 |